Cargando…
Is Tocilizumab Plus Dexamethasone Associated with Superinfection in Critically Ill COVID-19 Patients?
Background: Dexamethasone and tocilizumab are used to treat severely ill COVID-19 patients admitted to intensive care units (ICUs). We explored whether combination therapy increased the risk of superinfection compared to dexamethasone alone. Methods: This observational, retrospective study included...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573530/ https://www.ncbi.nlm.nih.gov/pubmed/36233432 http://dx.doi.org/10.3390/jcm11195559 |
_version_ | 1784810893884784640 |
---|---|
author | Camou, Fabrice Issa, Nahéma Hessamfar, Mojgan Guisset, Olivier Mourissoux, Gaëlle Pedeboscq, Stéphane Minot, Aimée Bonnet, Fabrice |
author_facet | Camou, Fabrice Issa, Nahéma Hessamfar, Mojgan Guisset, Olivier Mourissoux, Gaëlle Pedeboscq, Stéphane Minot, Aimée Bonnet, Fabrice |
author_sort | Camou, Fabrice |
collection | PubMed |
description | Background: Dexamethasone and tocilizumab are used to treat severely ill COVID-19 patients admitted to intensive care units (ICUs). We explored whether combination therapy increased the risk of superinfection compared to dexamethasone alone. Methods: This observational, retrospective study included critically ill COVID-19 adult patients admitted to our ICU because of respiratory failure. Patients received dexamethasone with (Group 1) or without (Group 2) tocilizumab. Data were collected from electronic medical files. Results: A total of 246 patients were included, of whom 150 received dexamethasone and tocilizumab, while 96 received dexamethasone alone. Acute respiratory distress syndrome was evident on admission in 226 patients, 56 of whom required mechanical ventilation (MV). Superinfections, mainly respiratory, were diagnosed in 59 patients, including 34/150 (23%) in Group 1 and 25/96 (26%) in Group 2 (p = 0.32). After multivariate analysis, the factors associated with a higher risk of superinfection included hematological malignancy (hazard ratio (HR): 2.47 (1.11–5.47), p = 0.03), MV (HR: 3.74 (1.92–7.26), p = 0.0001), and a higher SAPS-II score on admission (HR: 1.03 (1.01–1.06), p = 0.006). Conclusion: In critically ill COVID-19 patients, the addition of tocilizumab to dexamethasone was not associated with an increased risk of superinfection. |
format | Online Article Text |
id | pubmed-9573530 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95735302022-10-17 Is Tocilizumab Plus Dexamethasone Associated with Superinfection in Critically Ill COVID-19 Patients? Camou, Fabrice Issa, Nahéma Hessamfar, Mojgan Guisset, Olivier Mourissoux, Gaëlle Pedeboscq, Stéphane Minot, Aimée Bonnet, Fabrice J Clin Med Brief Report Background: Dexamethasone and tocilizumab are used to treat severely ill COVID-19 patients admitted to intensive care units (ICUs). We explored whether combination therapy increased the risk of superinfection compared to dexamethasone alone. Methods: This observational, retrospective study included critically ill COVID-19 adult patients admitted to our ICU because of respiratory failure. Patients received dexamethasone with (Group 1) or without (Group 2) tocilizumab. Data were collected from electronic medical files. Results: A total of 246 patients were included, of whom 150 received dexamethasone and tocilizumab, while 96 received dexamethasone alone. Acute respiratory distress syndrome was evident on admission in 226 patients, 56 of whom required mechanical ventilation (MV). Superinfections, mainly respiratory, were diagnosed in 59 patients, including 34/150 (23%) in Group 1 and 25/96 (26%) in Group 2 (p = 0.32). After multivariate analysis, the factors associated with a higher risk of superinfection included hematological malignancy (hazard ratio (HR): 2.47 (1.11–5.47), p = 0.03), MV (HR: 3.74 (1.92–7.26), p = 0.0001), and a higher SAPS-II score on admission (HR: 1.03 (1.01–1.06), p = 0.006). Conclusion: In critically ill COVID-19 patients, the addition of tocilizumab to dexamethasone was not associated with an increased risk of superinfection. MDPI 2022-09-22 /pmc/articles/PMC9573530/ /pubmed/36233432 http://dx.doi.org/10.3390/jcm11195559 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Camou, Fabrice Issa, Nahéma Hessamfar, Mojgan Guisset, Olivier Mourissoux, Gaëlle Pedeboscq, Stéphane Minot, Aimée Bonnet, Fabrice Is Tocilizumab Plus Dexamethasone Associated with Superinfection in Critically Ill COVID-19 Patients? |
title | Is Tocilizumab Plus Dexamethasone Associated with Superinfection in Critically Ill COVID-19 Patients? |
title_full | Is Tocilizumab Plus Dexamethasone Associated with Superinfection in Critically Ill COVID-19 Patients? |
title_fullStr | Is Tocilizumab Plus Dexamethasone Associated with Superinfection in Critically Ill COVID-19 Patients? |
title_full_unstemmed | Is Tocilizumab Plus Dexamethasone Associated with Superinfection in Critically Ill COVID-19 Patients? |
title_short | Is Tocilizumab Plus Dexamethasone Associated with Superinfection in Critically Ill COVID-19 Patients? |
title_sort | is tocilizumab plus dexamethasone associated with superinfection in critically ill covid-19 patients? |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573530/ https://www.ncbi.nlm.nih.gov/pubmed/36233432 http://dx.doi.org/10.3390/jcm11195559 |
work_keys_str_mv | AT camoufabrice istocilizumabplusdexamethasoneassociatedwithsuperinfectionincriticallyillcovid19patients AT issanahema istocilizumabplusdexamethasoneassociatedwithsuperinfectionincriticallyillcovid19patients AT hessamfarmojgan istocilizumabplusdexamethasoneassociatedwithsuperinfectionincriticallyillcovid19patients AT guissetolivier istocilizumabplusdexamethasoneassociatedwithsuperinfectionincriticallyillcovid19patients AT mourissouxgaelle istocilizumabplusdexamethasoneassociatedwithsuperinfectionincriticallyillcovid19patients AT pedeboscqstephane istocilizumabplusdexamethasoneassociatedwithsuperinfectionincriticallyillcovid19patients AT minotaimee istocilizumabplusdexamethasoneassociatedwithsuperinfectionincriticallyillcovid19patients AT bonnetfabrice istocilizumabplusdexamethasoneassociatedwithsuperinfectionincriticallyillcovid19patients |